GGrantIndex
← Search

Task V06: Process development and manufacture of cGMP compliant parvovirus B19 vaccine drug product for use in Phase I/II clinical trials

$2,093,700N01FY2019AINIH

Advanced Bioscience Laboratories, Inc., Kensington MD

Investigators

Abstract

The Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of services spanning product development planning and feasibility assessments; product optimization; product development and cGMP compliant manufacture for Phase I/II clinical studies; technical and facility audits; and regulatory support appropriate for submission to the U.S. Food and Drug Administration (FDA). These services will facilitate the development and introduction of new vaccines and biologics against a wide array of infectious diseases. This contract also provides for manufacture of candidate vaccines, vaccine components including adjuvants, vaccine delivery systems, other biologics, and challenge material.

View original record on NIH RePORTER →